Allegro Ophthalmicsllc Is A Late Stage Ophthalmic Biopharmaceutical Company Focused On Redefining The Retina Space With Integrin Inhibition Therapya Potential Market Disrupting Class Of Drugs For The Treatment Of Retinal Diseasesallegro S Lead Investigational Drugrisuteganibluminateaa Broad Spectrum Integrin Inhibitordownregulates Oxidative Stress Upstreamat Its Sourcesimultaneously Affecting All Four Pathways Of Oxidative Stress That Contribute To Retinal Diseases Such As Diabetic Macular Edemadmeand Nonexudative Age Related Macular Degenerationdry Amd Risuteganib Has Successfully Met The Endpoints For Three Phase 2 Studies And Is Preparing To Enter Phase 3 Studies In Dme During The First Half Of 2019Allegro Is Working Closely With The Global Retina Community To Bring To Market New Treatment Options For Leading Causes Of Blindness And Is Committed To Offering Patients An Improved Quality Of Life Sustained By Self Sufficientfunctional Vision
